Author

Enis H. Ozmert

Observed names: Enis H Ozmert, Enis Ozmert

Institution: Mayo Clinic

Observed institution: Mayo Clinic

ORCID: 0000-0001-6510-305X

Observed ORCID: 0000-0001-6510-305X

OpenAlex ID: A5116209857

Multiomics combined with machine learning defines unique molecular subtypes of cholangiocarcinoma and identifies TNK1 as a therapeutic target

2025 · Dong-Gi Mun, Erik Jessen, et al. · Hepatology · 3

Aptamer-directed, nanovesicle-mediated targeting of undruggable molecules in preclinical cholangiocarcinoma models

2025 · Mincheng Yu, Jack W. Sample, et al. · Hepatology · 2

19Aptamer-targeted delivery of siRNA therapeutics for cholangiocarcinoma

2026 · Brandon A Wilbanks, Ayano Kabashima, et al. · The Oncologist

14TEAD Inhibition by IAG933 as a Novel Therapeutic Strategy for Cholangiocarcinoma

2026 · Hidemi Nishi, Erik Jessen, et al. · The Oncologist

Abstract 7124: Resistance to the SFK inhibitor NXP900 in cholangiocarcinoma is characterized by IL13RA2-AKT signaling and can be overcome by combination therapy

2026 · Shelby K. Yee, Hendrien Kuipers, et al. · Cancer Research

Abstract 3081: TEAD inhibition by IAG933 as a novel therapeutic strategy for cholangiocarcinoma

2026 · Hidemi Nishi, Erik Jessen, et al. · Cancer Research

Cell-SELEX identifies a DNA aptamer for highly selective in vivo siRNA delivery in cholangiocarcinoma

2026 · Brandon A. Wilbanks, Ayano Kabashima, et al. · JHEP Reports

Battle of the NITs: MAF-5 leads the pack

2026 · Enis H. Ozmert · Hepatology

Multiomics-driven discovery of predictive biomarkers and strategies to overcome resistance to SFK-YAP inhibition in cholangiocarcinoma

2026 · Hendrien Kuipers, Danielle M. Carlson, et al. · bioRxiv (Cold Spring Harbor Laboratory)

Abstract 5588: Efficacy of TGR-5 inhibition in cholangiocarcinoma using the novel small molecule inhibitor SBI-364

2025 · Enis Ozmert, Jennifer L. Tomlinson, et al. · Cancer Research

Works count: 10

Citation count: 5

H-index: 2

I10-index: